Arch Biopartners Inc V.ARCH

182 Mil US Entry for a 20 Billion unmet market

[Riverfolk]

With Arch Biopartners Phase II trial currently having Data reviewed by a third party, the stock is currently trading at 182 mil (US) market cap with the potential to treat a 20 billion a year unmet market.

I recall posting something simular to this at 60 million, like then several will be upset they didnt buy.

[GoldenArm]

I don't even think that most people who got into this stock care of the potential. They are just in it for short term gain and this stock is golden right now. If Phase 3 gets going and IF results are great I think they get bought out fast. Just my humble opinion or fortune telling.

[Riverfolk]

I wont argue that there will be some trading happening on this momentum, but I have been a holder here for 4+ years and my network that controls near 2% are thinking long term. Coupled with the Insiders 58% and other long term holders, there is not as much available for the funds as one thinks. River

[2019champs]

Good point. It's a tight float. If the data is good, i don't see myself selling at $10-$15. I have been in this play for about 2 years and even if it takes another year or two to see $30-$40, il hold. I always thought $10 was a good number to take some off the table, but now i feel like it's selling short. Look, if BLU is trading at 700M cad market cap for chronic cough, i am holding